Scilex (SCLX) Competitors $22.80 +2.42 (+11.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$22.36 -0.44 (-1.93%) As of 09/5/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCLX vs. EOLS, ALMS, CMPX, TECX, KOD, ETON, ARCT, RGNX, ITOS, and ESPRShould you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Evolus (EOLS), Alumis (ALMS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Scilex vs. Its Competitors Evolus Alumis Compass Therapeutics Tectonic Therapeutic Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics REGENXBIO iTeos Therapeutics Esperion Therapeutics Evolus (NASDAQ:EOLS) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Do insiders & institutionals believe in EOLS or SCLX? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 5.9% of Evolus shares are owned by insiders. Comparatively, 7.9% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is EOLS or SCLX more profitable? Evolus has a net margin of -22.31% compared to Scilex's net margin of -179.12%. Scilex's return on equity of 0.00% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.31% -759.04% -24.63% Scilex -179.12%N/A -109.95% Do analysts prefer EOLS or SCLX? Evolus currently has a consensus target price of $21.25, indicating a potential upside of 177.42%. Scilex has a consensus target price of $455.00, indicating a potential upside of 1,895.61%. Given Scilex's higher probable upside, analysts clearly believe Scilex is more favorable than Evolus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Scilex 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to EOLS or SCLX? In the previous week, Evolus had 9 more articles in the media than Scilex. MarketBeat recorded 11 mentions for Evolus and 2 mentions for Scilex. Evolus' average media sentiment score of 1.59 beat Scilex's score of 0.68 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Scilex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, EOLS or SCLX? Evolus has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Scilex has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Which has stronger valuation and earnings, EOLS or SCLX? Evolus has higher revenue and earnings than Scilex. Evolus is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M1.86-$50.42M-$0.98-7.82Scilex$56.59M2.80-$72.81M-$29.02-0.79 SummaryEvolus beats Scilex on 10 of the 16 factors compared between the two stocks. Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCLX vs. The Competition Export to ExcelMetricScilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.59M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E Ratio-0.7921.1076.1526.11Price / Sales2.80466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book-0.829.8711.486.09Net Income-$72.81M-$53.42M$3.29B$266.51M7 Day Performance28.38%2.93%1.27%0.46%1 Month Performance52.92%9.85%7.94%4.59%1 Year Performance-37.36%15.74%62.94%26.04% Scilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCLXScilex2.0927 of 5 stars$22.80+11.9%$455.00+1,895.6%-41.3%$158.59M$56.59M-0.7980EOLSEvolus4.606 of 5 stars$7.63+1.5%$21.25+178.5%-48.9%$493.55M$266.27M-7.79170News CoveragePositive NewsShort Interest ↓ALMSAlumis3.0798 of 5 stars$4.64-1.3%$20.17+334.6%-61.7%$482.86MN/A0.00N/ACMPXCompass Therapeutics2.748 of 5 stars$3.49flat$12.89+269.3%+130.9%$482.61M$850K-7.7620Positive NewsTECXTectonic Therapeutic3.1274 of 5 stars$25.54-0.1%$80.33+214.5%-8.0%$477.91MN/A-6.32120News CoverageAnalyst ForecastKODKodiak Sciences3.1141 of 5 stars$9.04+0.8%$11.75+30.0%+324.2%$477.51MN/A-2.3890Trending NewsAnalyst RevisionETONEton Pharmaceuticals2.0094 of 5 stars$17.31+0.2%$29.67+71.4%+283.3%$464.21M$39.01M-108.1920Positive NewsARCTArcturus Therapeutics3.3811 of 5 stars$17.01-1.7%$50.57+197.3%-5.2%$461.90M$152.31M-7.63180Trending NewsAnalyst ForecastAnalyst RevisionRGNXREGENXBIO4.593 of 5 stars$8.93-0.9%$28.38+217.7%-14.7%$451.09M$83.33M-2.60370News CoveragePositive NewsGap UpITOSiTeos Therapeutics3.6902 of 5 stars$10.15flat$15.50+52.7%N/A$448.68M$35M-2.1790News CoverageShort Interest ↓ESPREsperion Therapeutics3.9443 of 5 stars$2.22+0.5%$7.00+215.3%+55.8%$447.60M$332.31M-4.53200Positive NewsOptions Volume Related Companies and Tools Related Companies EOLS Alternatives ALMS Alternatives CMPX Alternatives TECX Alternatives KOD Alternatives ETON Alternatives ARCT Alternatives RGNX Alternatives ITOS Alternatives ESPR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCLX) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCLX Stock Alerts